Appendix

From COVID-19
Jump to navigation Jump to search

APPENDIX

Stay-at-Home Advisories/Orders

Table A1 collects the current Stay-at-Home advisories (A) and orders by U.S. State with start and (current) end dates, the date of the first COVID-19 cases, the delay from initial cases, and the number of COVID-19 cases at the start date. A dash represents the absence of an advisory or order, while the word ‘Various’ denotes a state where each county has a different start and end date of their local advisory/order. Figure A1 indicates two distinct clusters of states that instituted Stay-at-Home advisories/orders.

Table A1. Start and End Dates of Stay-at-Home Advisories and Orders by State (May 8, 2020)
State or District
Date of Initial Reported Cases
Start Date
Delay [d]
Reported Cases by Start Date
End Date
Alabama
3/13
4/4
22
1,632
4/30
Alaska
3/12
3/28
16
102
4/24
Arizona
1/26
3/31
65
1,298
5/15
Arkansas
3/11
-
-
-
-
California
1/25
3/19
54
1,067
Colorado
3/5
3/26
21
1,432
4/26
Connecticut
3/8
3/23
15
415
5/20
Delaware
3/11
3/24
13
104
5/15
D.C.
3/7
3/30
23
401
5/15
Florida
3/1
4/3
33
10,260
5/4
Georgia
3/2
4/3
32
5,967
4/24
Hawaii
3/6
3/25
19
95
5/31
Idaho
3/13
3/25
12
123
5/1
Illinois
1/24
3/21
57
751
5/30
Indiana
3/6
3/25
19
479
5/1
Iowa
3/8
-
-
-
-
Kansas
3/7
3/30
23
373
5/4
Kentucky
3/6
3/26 (A)
20
248
5/11
Louisiana
3/9
3/23
14
1,172
5/15
Maine
3/12
4/2
21
376
5/31
Maryland
3/5
3/30
25
1,414
5/15
Massachusetts
2/1
3/24 (A)
52
1,159
5/18
Michigan
3/10
3/24
14
1,791
5/28
Minnesota
3/6
3/27
21
398
5/18
Mississippi
3/11
4/3
23
1,358
5/25
Missouri
3/7
4/6
30
2,722
5/3
Montana
3/13
3/28
15
147
4/26
Nebraska
2/18
-
-
-
-
Nevada
3/5
4/1
27
1,279
5/9
New Hampshire
3/2
3/27
25
187
5/31
New Jersey
3/4
3/21
17
1,336
New Mexico
3/11
3/24
13
100
5/31
New York
3/1
3/22
21
15,188
5/15
North Carolina
3/3
3/30
27
1,302
5/8
North Dakota
3/11
-
-
-
-
Ohio
3/9
3/23
14
444
5/29
Oklahoma
3/6
4/2 (A)
27
879
4/24
Oregon
2/28
3/23
24
191
Pennsylvania
3/6
4/1
26
5,805
5/1
Rhode Island
3/1
3/28
27
239
5/8
South Carolina
3/6
4/7
32
2,417
5/12
South Dakota
3/10
-
-
-
-
Tennessee
3/5
4/2
28
2,868
5/30
Texas
2/12
4/2
50
4,880
4/30
Utah
2/25
Various
-
-
-
Vermont
3/7
3/24
17
95
5/15
Virginia
3/7
3/30
23
1,020
6/10
Washington
1/21
3/23
62
2,101
5/31
West Virginia
3/17
3/23
6
16
5/4
Wisconsin
2/6
3/25
48
623
5/26[1]
Wyoming
3/11
Various
-
-
-
Figure A1: Cumulative COVID-19 Reported Cases at Start Time as a function of Delay from Day of Initial Report of COVID-19 Case(s)

Candidate Treatments/Vaccines Clinical Trials Progress

Tables A1a and A1b collect the primary action, number of clinical trials, and current progress of several compounds under investigation for the treatment of and vaccination for COVID-19.

Table A1a: Action and Clinical Trial Progress of Drug Candidates (September 26, 2020)
Compound
Action
U.S. / World Trials
U.S. Trial Phase (Count)
Completed
(U.S.)
Suspended
(U.S.)
Acalabrutinib
Bruton’s tyrosine kinase inhibitor
2/4
I(1), II(1)
0
0
Azithromycin
Antibiotic
21/76
I(1), II(13), III(8), IV(1)
7(2)
13(3)
Baricitinib
Tumor necrosis factor antagonist
4/14
II(2), III(3)
1(0)
0
BCG Vaccine
Tuberculosis Vaccine
1/19
IV(1)
0
0
Chloroquine
Immunosuppressive and Antiparasitic Drug
2/26
II(1), III(1)
2(0)
4(1)
Dexamethasone
Anti-inflammatory corticosteroid
3/25
II(1), III(1)
3(1)
2(0)
Famotidine
Histamine H2 receptor antagonist
3/6
III(1), IV(1)
1(1)
0
Favipiravir
Antiviral
2/33
II(2)
7(0)
1
Hydroxychloroquine
Immunosuppressive and Antiparasitic Drug
53/254
I(5), II(28), III(21), IV(6)
31(6)
29(9)
Ivermectin
Antiparasitic drug
3/39
II(2), III(1)
5(0)
0
Lopinavir
Antiretroviral, protease inhibitor
6/41
II(4), III(1, IV(1)
4(1)
2(0)
Losartan
Angiotensin II Receptor Antagonist
7/16
I(1), II(4), III(2), IV(1)
1(1)
1(0)
Methylprednisolone
Corticosteroid, Anti Inflammatory Drug
4/22
II(2), III(1), IV(1)
6(2)
0
Remdesivir
Antiviral
17/29
I(2), II(5), III(11)
5(4)
2(0)
Ritonavir
Antiretroviral, protease inhibitor
6/45
II(4), III(1), IV(1)
5(0)
2(0)
Sarilumab
Human Monoclonal Antibody against interleukin-6 receptor
3/11
II(2), III(1), IV(1)
1(0)
1(0)
Siltuximab
Anti interleukin-6 Chimerical Monoclonal Antibody
0/4
-
1(0)
0
Tocilizumab
Monoclonal Antibody against interleukin-6 receptor
14/47
II(6), III(7), IV(1)
6(4)
5(2)
Umifenovir
Antiviral
0/5
-
0
0


Table A1b: Action Clinical Trial Progress of Vaccine Candidates (September 7, 2020)
Candidate
Action
U.S. / World Trials
Trial Phase (Count)
Completed
(U.S.)
Suspended
(U.S.)
Ad5-nCoV
Adenovirus vectored vaccine encoding full SARS-CoV-2 Spike Protein
0/4
I(2), II(3), III(1)
0
0
Ad26.COV2.S
Adenovirus vectored vaccine
2/4
I(2), II(2), III(1)
0
0
BNT162 (a1, b1, b2, c1)
mRNA-based vaccines encoding SARS-Cov-2 RBD
1/4
I(3), II(3), III(1)
0
0
AZD1222 (ChAdOx1 nCoV-2019)
Adenovirus vectored vaccine encoding full SARS-CoV-2 Spike Protein
1/5
I(2), II(3), III(3)
0
0
CoronaVac
Inactivated whole SARS-CoV-2 virus
0/4
I(2), II(2), III(2)
0
0
Gam-COVID-
Vac Lyo
Adenovirus vectored vaccine encoding SARS-CoV-2 Spike Protein
0/3
I(2), II(2), III(1)
2
0
INO-4800
DNA-based vaccine encoding SARS-CoV-2 Spike Protein
1/2
I(2), II(1)
0
0
mRNA-1273
mRNA-based vaccine encoding full SARS-Cov-2 Spike Protein
3/3
I(1), II(1), III(1)
0
0
NVX-CoV2373
Recombinant Spike Protein Vaccine
0/1
II(1)
0
0
  1. The Wisconsin Supreme Court overturned the Stay-at-Home Order in a 4-3 decision on May 13, 2020.